Daniel Engelman to Antibodies, Monoclonal, Humanized
This is a "connection" page, showing publications Daniel Engelman has written about Antibodies, Monoclonal, Humanized.
Connection Strength
0.841
-
Ostermann M, Corteville DC, Doi K, Koyner JL, Lamy A, Li G, Solinsky CM, Winterberg PD, Smith WT, Mehta RL, Murray PT, Shaw AD, Zarbock A, Engelman DT. A phase 3 study of ravulizumab to protect patients with chronic kidney disease from cardiac surgery-associated acute kidney injury and major adverse kidney events (ARTEMIS). Trials. 2025 May 30; 26(1):181.
Score: 0.841